Emergency endovascular aneurysm repair showed no clear difference in complication: myocardial infarction (30‐day) compared with conventional open repair (low certainty).
Emergency endovascular aneurysm repair showed no clear difference in complication: renal complications (moderate or severe) (30‐day) compared with conventional open repair (low certainty).
Emergency endovascular aneurysm repair showed no clear difference in complication: respiratory failure (30‐day) compared with conventional open repair (low certainty).
Emergency endovascular aneurysm repair may leads to lower complication: bowel ischaemia (30‐day) compared with conventional open repair (low certainty).
Emergency endovascular aneurysm repair showed no clear difference in mortality (6 months) compared with conventional open repair (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether neuroprotection changes visual field: the proportion of participants with progression of… compared with control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether neuroprotection changes intraocular pressure: mean IOP at 4 years' compared with control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether neuroprotection changes adverse effects: ocular allergy to the study medication requiring… compared with control (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).
Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).
Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).
Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).